Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Treasury Shares: 2014-2024

  • Ocular Therapeutix's Treasury Shares rose 108.29% to $3.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $3.4 million, marking a year-over-year increase of 108.29%. This contributed to the annual value of $3.4 million for FY2024, which is 108.29% up from last year.
  • Latest data reveals that Ocular Therapeutix reported Treasury Shares of $3.4 million as of Q4 2024, which was up 108.29% from $1.6 million recorded in Q4 2023.
  • In the past 5 years, Ocular Therapeutix's Treasury Shares registered a high of $3.4 million during Q4 2024, and its lowest value of $1.1 million during Q4 2022.
  • Moreover, its 3-year median value for Treasury Shares was $1.6 million (2023), whereas its average is $2.0 million.
  • Data for Ocular Therapeutix's Treasury Shares shows a peak YoY soared of 108.29% (in 2024) over the last 5 years.
  • Over the past 3 years, Ocular Therapeutix's Treasury Shares (Quarterly) stood at $1.1 million in 2022, then soared by 48.93% to $1.6 million in 2023, then skyrocketed by 108.29% to $3.4 million in 2024.
  • Its Treasury Shares was $3.4 million in Q4 2024, compared to $1.6 million in Q4 2023 and $1.1 million in Q4 2022.